These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 27035571)

  • 1. Magnetic Resonance Imaging Features of the Nigrostriatal System: Biomarkers of Parkinson's Disease Stages?
    Hopes L; Grolez G; Moreau C; Lopes R; Ryckewaert G; Carrière N; Auger F; Laloux C; Petrault M; Devedjian JC; Bordet R; Defebvre L; Jissendi P; Delmaire C; Devos D
    PLoS One; 2016; 11(4):e0147947. PubMed ID: 27035571
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Magnetic resonance imaging markers of Parkinson's disease nigrostriatal signature.
    Péran P; Cherubini A; Assogna F; Piras F; Quattrocchi C; Peppe A; Celsis P; Rascol O; Démonet JF; Stefani A; Pierantozzi M; Pontieri FE; Caltagirone C; Spalletta G; Sabatini U
    Brain; 2010 Nov; 133(11):3423-33. PubMed ID: 20736190
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Social enrichment attenuates nigrostriatal lesioning and reverses motor impairment in a progressive 1-methyl-2-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease.
    Goldberg NR; Fields V; Pflibsen L; Salvatore MF; Meshul CK
    Neurobiol Dis; 2012 Mar; 45(3):1051-67. PubMed ID: 22198503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MRI detects acute degeneration of the nigrostriatal dopamine system after MPTP exposure in hemiparkinsonian monkeys.
    Miletich RS; Bankiewicz KS; Quarantelli M; Plunkett RJ; Frank J; Kopin IJ; Di Chiro G
    Ann Neurol; 1994 Jun; 35(6):689-97. PubMed ID: 8210225
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brain α7 nicotinic acetylcholine receptors in MPTP-lesioned monkeys and parkinsonian patients.
    Morissette M; Morin N; Grégoire L; Rajput A; Rajput AH; Di Paolo T
    Biochem Pharmacol; 2016 Jun; 109():62-69. PubMed ID: 27038656
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease.
    Novikova L; Garris BL; Garris DR; Lau YS
    Neuroscience; 2006 Jun; 140(1):67-76. PubMed ID: 16533572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Substantia Nigra Neuromelanin as an Imaging Biomarker of Disease Progression in Parkinson's Disease.
    Fabbri M; Reimão S; Carvalho M; Nunes RG; Abreu D; Guedes LC; Bouça R; Lobo PP; Godinho C; Coelho M; Gonçalves NC; Rosa MM; Antonini A; Ferreira JJ
    J Parkinsons Dis; 2017; 7(3):491-501. PubMed ID: 28671143
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum cholesterol and nigrostriatal R2* values in Parkinson's disease.
    Du G; Lewis MM; Shaffer ML; Chen H; Yang QX; Mailman RB; Huang X
    PLoS One; 2012; 7(4):e35397. PubMed ID: 22530017
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of striatonigral connectivity using probabilistic tractography in Parkinson's disease.
    Theisen F; Leda R; Pozorski V; Oh JM; Adluru N; Wong R; Okonkwo O; Dean DC; Bendlin BB; Johnson SC; Alexander AL; Gallagher CL
    Neuroimage Clin; 2017; 16():557-563. PubMed ID: 28971007
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Iron accumulation in the substantia nigra of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced hemiparkinsonian monkeys.
    Mochizuki H; Imai H; Endo K; Yokomizo K; Murata Y; Hattori N; Mizuno Y
    Neurosci Lett; 1994 Feb; 168(1-2):251-3. PubMed ID: 8028787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Magnetic resonance imaging-based volumetric analysis of basal ganglia nuclei and substantia nigra in patients with Parkinson's disease.
    Geng DY; Li YX; Zee CS
    Neurosurgery; 2006 Feb; 58(2):256-62; discussion 256-62. PubMed ID: 16462479
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Magnetic resonance imaging and tensor-based morphometry in the MPTP non-human primate model of Parkinson's disease.
    Modo M; Crum WR; Gerwig M; Vernon AC; Patel P; Jackson MJ; Rose S; Jenner P; Iravani MM
    PLoS One; 2017; 12(7):e0180733. PubMed ID: 28738061
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is R2* a new MRI biomarker for the progression of Parkinson's disease? A longitudinal follow-up.
    Ulla M; Bonny JM; Ouchchane L; Rieu I; Claise B; Durif F
    PLoS One; 2013; 8(3):e57904. PubMed ID: 23469252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Region-specific disturbed iron distribution in early idiopathic Parkinson's disease measured by quantitative susceptibility mapping.
    He N; Ling H; Ding B; Huang J; Zhang Y; Zhang Z; Liu C; Chen K; Yan F
    Hum Brain Mapp; 2015 Nov; 36(11):4407-20. PubMed ID: 26249218
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distinct progression pattern of susceptibility MRI in the substantia nigra of Parkinson's patients.
    Du G; Lewis MM; Sica C; He L; Connor JR; Kong L; Mailman RB; Huang X
    Mov Disord; 2018 Sep; 33(9):1423-1431. PubMed ID: 29756399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Damage to the nigrostriatal system in the MPTP-treated SAMP8 mouse.
    Liu J; Wang YY; Liu L; Wang QD; Yuan ZY; Zhang ZX; Gu P; Wang MW
    Neurosci Lett; 2008 Dec; 448(2):184-8. PubMed ID: 18977411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of striatal silent lacunar infarction on the substantia nigra and movement disorders in Parkinson's disease: A follow-up study.
    Zhang G; Zhang C; Zhang Y; Wang Y; Nie K; Zhang B; Xie H; Lu J; Wang L
    Parkinsonism Relat Disord; 2017 Oct; 43():33-37. PubMed ID: 28688982
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progression marker of Parkinson's disease: a 4-year multi-site imaging study.
    Burciu RG; Ofori E; Archer DB; Wu SS; Pasternak O; McFarland NR; Okun MS; Vaillancourt DE
    Brain; 2017 Aug; 140(8):2183-2192. PubMed ID: 28899020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitative assessment of iron deposition in the midbrain using 3D-enhanced T2 star weighted angiography (ESWAN): a preliminary cross-sectional study of 20 Parkinson's disease patients.
    Wang C; Fan G; Xu K; Wang S
    Magn Reson Imaging; 2013 Sep; 31(7):1068-73. PubMed ID: 23746648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biomarkers of Parkinson's disease: Striatal sub-regional structural morphometry and diffusion MRI.
    Khan AR; Hiebert NM; Vo A; Wang BT; Owen AM; Seergobin KN; MacDonald PA
    Neuroimage Clin; 2019; 21():101597. PubMed ID: 30472168
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.